ArticleNature immunology2024
Vaccination induces broadly neutralizing antibody precursors to HIV gp41.
Erratum issuedAbstract read
In one paragraph
Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.Science translational medicine · 2025Trial
- Article
- Article
- Structural basis of membrane engagement and polyreactivity control in HIV-1 MPER broadly neutralizing antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Deep mining of the human antibody repertoire identifies frequent and genetically diverse CDRH3 topologies targetable by vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Deep learning-enabled scaffolding of spatial arrays of PfCSP epitopes.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques.Immunity · 2026Article
- Decoding the glycan shield: Immune recognition and response to the HIV-1 envelope trimer.The Journal of biological chemistry · 2026Review
- Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human VProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Early clonal dominance at priming sets the trajectory for broad HIV serum neutralization.bioRxiv : the preprint server for biology · 2026Article
- Nanoparticle Immunoadjuvant Complexes Augment Germinal Center Responses to Vaccination.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates.Nature immunology · 2026Article
- Virus glycoprotein nanodisc platform for vaccine analytics.Nature communications · 2026Article
- HIV Membrane-Proximal External Region Scaffolded Immunogen as Killed Whole-Cell Genome-Reduced Vaccines.Viruses · 2026Article
- Cryo-EM structures of antibodies elicited by germline-targeting HIV MPER epitope scaffolds.Cell reports · 2026Article
- Functional Convergence of Genetically Diverse B-Cell Receptors in Simian-HIV Infected Rhesus Macaques.bioRxiv : the preprint server for biology · 2026Article
- Accelerating Innovation: Advancing Opportunities in HIV Vaccine Development.Current HIV research · 2026Review
- Research progress on HIV-1 structural proteins and antiviral therapies.Frontiers in immunology · 2026Review
- Unveiling an Immunological Mystery: Deciphering the Durability Divide in Vaccine-Elicited Antibody Responses.Current HIV research · 2026Review
- Integration of Preclinical and Clinical Vaccine Safety and Immunogenicity Testing for Development of a Pediatric HIV Vaccine to Achieve Protective HIV Immunity Prior to Adolescence.Current HIV research · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
75 authors.
Torben Schiffner *Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Ivy Phung *Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7283-4766
Rashmi Ray *The Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Adriana Irimia *IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
Ming Tian *Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
Olivia SwansonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-8162-8358
Jeong Hyun LeeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Chang-Chun D LeeIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-5470-2484
Ester Marina-ZárateCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1586-404X
So Yeon ChoIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
Jiachen HuangIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
Gabriel OzorowskiIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9695-8138
Patrick D SkogDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Andreia M SerraDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Kimmo RantalainenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3158-9183
Joel D AllenSchool of Biological Sciences, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0003-2547-968X
Sabyasachi BabooDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-4547-5160
Oscar L RodriguezDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.ORCID http://orcid.org/0000-0002-4587-6124
Sunny HimansuModerna, Inc., Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7954-9674
Jianfu ZhouDepartment of Computer Science, Dartmouth College, Hanover, NH, USA.
Jonathan HurtadoDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Claudia T FlynnDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Katherine McKenneyDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Colin Havenar-DaughtonCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Swati SahaDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.ORCID http://orcid.org/0009-0004-7210-6338
Kaitlyn ShieldsDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
Steven SchultzeDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
Melissa L SmithDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
Chi-Hui LiangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Laura ToyCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Simone PecettaThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9898-4324
Ying-Cing LinThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3534-7974
Jordan R WillisDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-0135-5263
Fabian SesterhennDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Daniel W KulpDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-0527-3804
Xiaozhen HuDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Christopher A CottrellDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-3364-3083
Xiaoya ZhouDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Jennifer RuizDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Xuesong WangThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Usha NairThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Kathrin H KirschThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA.
Hwei-Ling ChengHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
Jillian DavisHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
Oleksandr KalyuzhniyDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-5273-1951
Alessia LiguoriDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Jolene K DiedrichDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.
Julia T NgoDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Vanessa LewisDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Nicole PhelpsDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Ryan D TingleDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Skye SpencerDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Erik GeorgesonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-5137-4625
Yumiko AdachiDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Michael KubitzDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Saman EskandarzadehDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Marc A ElsligerIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
Rama R AmaraDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-6309-6797
Elise LandaisDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-8183-5565
Bryan BrineyDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Dennis R BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-6711-9864
Diane G CarnathanDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Guido SilvestriDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-6602-2470
Corey T WatsonDepartment of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.ORCID http://orcid.org/0000-0001-7248-8787
John R YatesDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-5267-1672
James C PaulsonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-4589-5322
Max CrispinSchool of Biological Sciences, University of Southampton, Southampton, UK.ORCID http://orcid.org/0000-0002-1072-2694
Gevorg GrigoryanDepartment of Computer Science, Dartmouth College, Hanover, NH, USA.ORCID http://orcid.org/0000-0003-4645-7666
Andrew B WardIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-7153-3769
Devin SokDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9354-1740
Frederick W AltHoward Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0583-1271
Ian A WilsonIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA. wilson@scripps.edu.ORCID http://orcid.org/0000-0002-6469-2419
Facundo D BatistaThe Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, USA. fbatista1@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-1130-9463
Shane CrottyCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVD), The Scripps Research Institute, La Jolla, CA, USA. shane@lji.org.ORCID http://orcid.org/0000-0002-6484-6262
William R SchiefDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. schief@scripps.edu.ORCID http://orcid.org/0000-0002-1120-0150
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MYerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MVirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4MUser Training & OutreachP30GM138396 · NIGMS · UCHICAGO ARGONNE, LLC · PI ROBERT F. FISCHETTI · 2020 to 2026
$34.3MB and T Cell Biology of Protection from and Eradication of SIV/SHIV InfectionUM1AI169662 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Eric Hunter · 2022 to 2026
$32.0MNonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1MViral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2018 to 2026
$17.5MUniversity of Louisville Center for Integrative Environmental Health SciencesP30ES030283 · NIEHS · UNIVERSITY OF LOUISVILLE · PI Amanda Jo LeBlanc · 2020 to 2026
$10.0MDesign and testing of immunogens to elicit 10E8-like broadly neutralizing antibodies against HIVR01AI147826 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SCHIFFNER, TORBEN · 2019 to 2025
$8.0MKentucky Network for Innovation & Commercialization (“KYNETIC”)U01HL152392 · NHLBI · UNIVERSITY OF KENTUCKY · PI DWOSKIN, LINDA P, MERTEN, KEVYN E · 2019 to 2022
$3.9MBill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) INV046626Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) NV-007522Gates Foundation INV-002916Gates Foundation INV-007522Gates Foundation INV-008813Gates Foundation INV-009585NHLBI NIH HHS U01 HL152392NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI147826NIAID NIH HHS U24 AI126683NIAID NIH HHS UM1 AI144462NIAID NIH HHS UM1 AI169662NIEHS NIH HHS P30 ES030283NIGMS NIH HHS P30 GM138396NIH HHS P51 OD011132NIH HHS U42 OD011023U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI144462U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI147826
Abstract
A key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of priming immunogens that induce rare bnAb-precursor B cells. The high neutralization breadth of the HIV bnAb 10E8 makes elicitation of 10E8-class bnAbs desirable; however, the recessed epitope within gp41 makes envelope trimers poor priming immunogens and requires that 10E8-class bnAbs possess a long heavy chain complementarity determining region 3 (HCDR3) with a specific binding motif. We developed germline-targeting epitope scaffolds with affinity for 10E8-class precursors and engineered nanoparticles for multivalent display. Scaffolds exhibited epitope structural mimicry and bound bnAb-precursor human naive B cells in ex vivo screens, protein nanoparticles induced bnAb-precursor responses in stringent mouse models and rhesus macaques, and mRNA-encoded nanoparticles triggered similar responses in mice. Thus, germline-targeting epitope scaffold nanoparticles can elicit rare bnAb-precursor B cells with predefined binding specificities and HCDR3 features.
Indexed as
AIDS VaccinesAntibodies, NeutralizingHIV-1HIV AntibodiesHIV Envelope Protein gp41HIV InfectionsMacaca mulattaAnimalsB-LymphocytesBroadly Neutralizing AntibodiesComplementarity Determining RegionsEpitopesFemaleHumansMiceNanoparticlesAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing AntibodiesComplementarity Determining RegionsEpitopesHIV AntibodiesHIV Envelope Protein gp41
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.